Corrigendum: Precautions in the management of opioid agonist therapy: from target population characteristics to new formulations and post-marketing monitoring – a focus on the Italian system

Guido Mannaioni, Fabio Lugoboni

Article Type

Corrigendum

Published

The authors wish to make the following corrections to their article: Mannaioni G, Lugoboni F. Precautions in the management of opioid agonist therapy: from target population characteristics to new formulations and post-marketing monitoring – a focus on the Italian system. Drugs Context. 2023;12:2023-2-6. https://doi.org/10.7573/dic.2023-2-6

Read more

Precautions in the management of opioid agonist therapy: from target population characteristics to new formulations and post-marketing monitoring – a focus on the Italian system

Guido Mannaioni, Fabio Lugoboni

Article Type

Review

Published

This articles aims is to provide useful information and insights for the management of opioid agonist therapy by providing an overview that ranges from the characteristics of opioid use disorder patients to the macroscopic phenomena of social-health significance on a national scale, with a particular focus on the Italian territory.

Read more

Individuals at risk for severe COVID-19 in whom ritonavir-containing therapies are contraindicated or may lead to interactions with concomitant medications: a retrospective analysis of German health insurance claims data

Christoph Lübbert, Igor Dykukha, Jann-Patrick Pelz, Helen Yearley, Wolfgang Junker, Nina Gruber, Sibyll Escher, Katrin Biereth, Sima Melnik, Julia Puschmann

Article Type

Review

Published

This article aimed to assess the prevalence of individuals with one or more risk factors for severe COVID-19 along with contraindications and potential drug–drug interactions due to ritonavir-containing COVID-19 therapy.

Read more

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.